CClinicalTrials.gg
Sign In
CompletedNCT02261337Updated Nov 1, 2022

Is Gait Speed and Sarcopenia Prognostic in Chronic Respiratory Disease?

An observational study in Chronic Obstructive Pulmonary Disease and Allied Conditions, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
565
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to assess usual walking speed (4-metre gait speed) and markers of sarcopenia predict mortality in patients with chronic respiratory disease.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease and Allied Conditions

Keywords

  • Sarcopenia
03

In context

Lung Diseases, Obstructive

2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.

This study's enrollment of 565 is above the median of 150 across 639 observational studies indexed under Lung Diseases, Obstructive.

Browse Lung Diseases, Obstructive studies →

Lead sponsor

Royal Brompton & Harefield NHS Foundation Trust is the lead sponsor of 137 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patient with chronic respiratory disease. The cohort will be recruited from Harefield hospital.

Inclusion criteria

  • All patients with chronic respiratory disease who are able to complete the assessments.

Exclusion criteria

Exclusion Criteria:

  • Significant co-morbidities that would limit walking ability, exercise capacity or make exercise unsafe (e.g. unstable ischaemic heart disease, neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation).
  • Any patient whom the Chief Investigator feels it is unsafe to exercise (e.g. unstable cardiovascular disease).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
565 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of participant deaths

    Time frame: 1 year

Secondary outcomes

  1. Number of participant deaths

    Time frame: 2 years and 5 years

  2. Number of exacerbations as defined by a worsening of symptoms that warrant a change in medication.

    Time frame: 1 and 2 years

  3. Number of hospital admissions

    Time frame: 1 and 2 years

  4. Number of patients admitted to a nursing home

    Time frame: 2 and 5 years

  5. Number of hospital bed days

    Time frame: 1 and 2 years

07

Study locations

1 site
  • Harefield hospital
    Harefield, Middlesex UB96JH, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02261337
Lead sponsor
Royal Brompton & Harefield NHS Foundation Trust
Collaborators
Medical Research Council
Responsible party
Sponsor
First posted
Oct 10, 2014
Start date
Dec 2013
Primary completion
Apr 2018
Completion
Apr 2022
Last update
Nov 1, 2022

Study contacts

William DC Man, FRCP PhD
principal investigator · NIHR Respiratory Biomedical Research Unit Royal Brompton & Harefield NHS Foundation Trust
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Diseases, Obstructive→

Other studies from this sponsor

Royal Brompton & Harefield NHS Foundation Trust

Start the discussion